Publications by authors named "Richard Harrop"

Claim this Profile
T
Targeting Tumor Antigen 5T4 Using CAR T Cells for the Treatment of Acute Myeloid Leukemia.
Richard Harrop, Daniel G Blount, Naeem Khan, Mayowa Soyombo, Laura Moyce

Mol Cancer Ther· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC).
Agnieszka Michael, William Wilson, Sunny Sunshine, Nicola Annels, Richard Harrop

Int J Gynecol Cancer· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
Federica Cappuccini, Richard Bryant, Emily Pollock, Lucy Carter, Clare Verrill, Richard Harrop

J Immunother Cancer· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer stem cell mobilization and therapeutic targeting of the 5T4 oncofetal antigen.
Richard Harrop, Eric O'Neill, Peter L Stern

Ther Adv Vaccines Immunother· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial.
Jason F Lester, Angela C Casbard, Saly Al-Taei, Richard Harrop, Lajos Katona

Oncoimmunology· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Assessment of CAR T-Cell Therapy Targeting the Tumor Antigen 5T4 in Ovarian Cancer.
Gemma L Owens, Victoria E Sheard, Milena Kalaitsidou, Daniel Blount, Yatish Lad, Richard Harrop

J Immunother· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer.
Martin Scurr, Tom Pembroke, Anja Bloom, David Roberts, Amanda Thomson, Richard Harrop

Clin Cancer Res· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Modified Vaccinia Ankara-5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Martin Scurr, Tom Pembroke, Anja Bloom, David Roberts, Amanda Thomson, Richard Harrop

JAMA Oncol· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
5
5T4 oncofoetal antigen: an attractive target for immune intervention in cancer.
Peter L Stern, Richard Harrop

Cancer Immunol Immunother· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lentiviral Vector Gene Transfer of Endostatin/Angiostatin for Macular Degeneration (GEM) Study.
Peter A Campochiaro, Andreas K Lauer, Elliott H Sohn, Tahreem A Mir, Stuart Naylor, Richard Harrop

Hum Gene Ther· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial.
Stéphane Palfi, Jean Marc Gurruchaga, G Scott Ralph, Helene Lepetit, Sonia Lavisse, Richard Harrop

Lancet· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccination of castration-resistant prostate cancer patients with TroVax (MVA-5T4) in combination with docetaxel: a randomized phase II trial.
Richard Harrop, Franklin Chu, Nashat Gabrail, Sandy Srinivas, Daniel Blount

Cancer Immunol Immunother· September 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer vaccines: identification of biomarkers predictive of clinical efficacy.
Richard Harrop

Hum Vaccin Immunother· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax).
Richard Harrop, Peter Treasure, Jackie de Belin, Michelle Kelleher, Gemma Bolton

Cancer Immunol Immunother· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies.
Adrian Bot, Mark Ahn, Marnix Bosch, Dirk Brockstedt, Lisa H Butterfield, Richard Harrop

J Transl Med· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model.
Scott S Tykodi, Shoko Satoh, Janise D Deming, Jeffrey Chou, Richard Harrop

J Immunother· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overexpression and potential targeting of the oncofoetal antigen 5T4 in malignant pleural mesothelioma.
Saly Al-Taei, Josephine Salimu, Jason F Lester, Seamus Linnane, Madusha Goonewardena, Richard Harrop

Lung Cancer· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients.
Richard Harrop, William H Shingler, Mike McDonald, Peter Treasure, Robert J Amato

Cancer Immunol Immunother· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients.
Richard Harrop, William Shingler, Michelle Kelleher, Jackie de Belin, Peter Treasure

J Immunother· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study.
Robert J Amato, Robert E Hawkins, Howard L Kaufman, John A Thompson, Piotr Tomczak, Richard Harrop

Clin Cancer Res· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting targeted therapies.
William Shingler, Richard Harrop

Immunotherapy· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4).
Eyad Elkord, Adam Dangoor, Deborah J Burt, Thomas D Southgate, Sai Daayana, Richard Harrop

Cancer Immunol Immunother· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial.
Robert J Amato, William Shingler, Madusha Goonewardena, Jackie de Belin, Stuart Naylor, Richard Harrop

J Immunother· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-alpha.
Robert E Hawkins, Catriona Macdermott, Alaaeldin Shablak, Caroline Hamer, Fiona Thistlethwaite, Richard Harrop

J Immunother· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.
Howard L Kaufman, Bret Taback, William Sherman, Dae Won Kim, William H Shingler, Richard Harrop

J Transl Med· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis